SaMD(Software-as-a-Medical Device) 분야 생성형 AI 시장 : 시장 점유율 분석, 업계 동향 및 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the generative AI in Software as a Medical Device Market size was valued at USD 3.70 billion in 2025 and is estimated to grow from USD 4.38 billion in 2026 to reach USD 10.19 billion by 2031, at a CAGR of 18.40% during the forecast period (2026-2031).

This report is Segmented by Software Function (8 Segments), Clinical Use Case (Radiology, Pathology, Oncology, Cardiology, Neurology, and More), Deployment (Cloud-Based, On-Premises, Hybrid), End User (Hospitals, Ambulatory Care Centers, Diagnostic Labs, Specialty Clinics, Academic Medical Centers), and Geography (North America, Europe, Asia-Pacific, MEA, South America). Forecasts are in Terms of Value (USD).

Global Generative AI In Software As A Medical Device (SaMD) Market Trends and Insights

Growth of AI-Assisted Clinical Documentation

Clinical documentation remained one of the most immediate use cases for generative AI in SaMD market products, as it consumed substantial clinician time. A 2026 evaluation at two US academic medical centers reported high usability scores for an ambient AI scribe and meaningful reductions in after-hours documentation time. A 2026 study across six health systems found that ambulatory clinician burnout declined from 51.9% to 38.8% within 30 days of ambient scribe adoption. NHS England issued updated guidance for AI-enabled ambient scribing products in April 2026, supporting wider deployment where products met local governance and clinical safety requirements.

Clinician Shortages and Diagnostic Workflow Pressure

Workforce shortages made automation a practical requirement for many care providers in the generative AI in SaMD market. The American Medical Association reported that 41.9% of physicians had at least one symptom of burnout in 2025, while 57% of surveyed physicians identified administrative automation as the leading AI opportunity in their practices. Generative tools helped draft preliminary reports and organize documentation, supporting clinical throughput without replacing professional review. In June 2026, Aidoc received FDA Breakthrough Device Designation for First Read, which analyzed chest radiographs and generated preliminary radiology report text.

Hallucination and Non-Deterministic Clinical Outputs

Generative models can create failure modes that differ from those of conventional diagnostic software. A 2025 study in Communications Medicine tested large language models with clinical prompts containing a fabricated element and reported hallucination rates of 50% to 83% across the tested models. The findings showed that accuracy checks should not rely on a single model release. A 2026 npj Digital Medicine article described unconfined non-deterministic clinical software as a distinct regulatory challenge for healthcare. Errors in administrative documentation can also influence clinical decisions, claims, and medication management, making human review, traceable outputs, and post-market monitoring key safeguards for the generative AI in SaMD market.

Other drivers and restraints analyzed in the detailed report include:

1. Regulatory Pathways for Managed Algorithm Changes
2. Rising Demand for Scalable Clinical Decision Support
3. Patient-Level Data Governance and Provenance Constraints

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Diagnostic Interpretation and Reporting is expected to account for a 29.55% share in 2025, making it the largest software function in the generative AI in SaMD market. This position reflects the established validation history of imaging AI and its expansion from image detection to report preparation. Remote Monitoring and Patient Management is forecast to register the fastest growth, at a CAGR of 21.93% through 2031, as care models place greater emphasis on continuous monitoring. Clinical Documentation and Ambient Scribing records the highest deployment volume among functional categories, supported by Microsoft's March 2025 launch of Dragon Copilot, which combined DAX Copilot and Dragon Medical One and was deployed across more than 400 healthcare organizations, processing more than 100 million patient encounters.

Therapeutic Planning and Personalization, along with Clinical Trial and Evidence Generation Support, remains a smaller function in the generative AI in SaMD market. Higher requirements for tools that influence treatment decisions and longer validation periods before payer adoption constrain their growth. Clinical Decision Support and Medical Coding and Revenue-Cycle Support occupy the middle range of the functional mix, while coding tools benefit from generative models that interpret unstructured notes and suggest ICD-10 and CPT codes in context. Tempus acquired Paige for USD 81.25 million in 2025, and the resulting pathology foundation model draws on nearly 7 million digitized slides to support Paige Predict, which predicts 123 molecular biomarkers across 16 cancer types from routine H&E images.

Radiology and Imaging is expected to account for a 34.22% share in 2025 and remain the largest clinical use case in the generative AI in SaMD market. Imaging datasets provide detailed visual information that supports model development and evaluation. Cardiology is forecast to expand at a CAGR of 22.67% through 2031, the fastest rate among the listed clinical use cases. The supplied draft recorded 97 FDA-cleared cardiovascular AI and machine learning SaMD devices through the first quarter of 2026 and stated that more than one-third of cardiology AI clearances in FDA history occurred in the prior three years.

Pathology and Oncology are becoming more important use cases as AI moves from single-cancer detection to biomarker prediction, supporting treatment selection where models are validated for the intended setting. EchoNext received FDA clearance after validation on more than 700,000 ECG-echocardiogram pairs and can detect six types of structural heart disease from a standard 12-lead ECG. This example shows how software can increase the diagnostic value of existing equipment. Neurology, Ophthalmology, Gastroenterology, and Women's Health remain earlier-stage areas, although adaptable models continue to support development across specialties.

Complete Report Scope:

• By Software Function
  • Clinical Documentation and Ambient Scribing
  • Clinical Decision Support
  • Diagnostic Interpretation and Reporting
  • Patient Communication and Triage
  • Therapeutic Planning and Personalization
  • Remote Monitoring and Patient Management
  • Medical Coding and Revenue-Cycle Support
  • Clinical Trial and Evidence Generation Support
• By Clinical Use Case
  • Radiology and Imaging
  • Pathology
  • Oncology
  • Cardiology
  • Neurology
  • Ophthalmology
  • Gastroenterology
  • Women's Health
  • Others
• By Deployment
  • Cloud-Based
  • On-Premises
  • Hybrid
• By End User
  • Hospitals and Health Systems
  • Ambulatory Care Centers
  • Diagnostic Laboratories
  • Specialty Clinics
  • Academic Medical Centers
  • Others
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America held a 41.25% share in 2025, making it the leading regional contributor to the generative AI in SaMD market. The United States remained the largest national market for AI medical device development and clearance activity. The supplied draft states that the FDA authorized more than 295 new AI and machine learning medical devices in 2025, with 62% classified as SaMD and 63% classified as diagnostic devices. Canada and Mexico remained smaller but growing adoption centers, supported by links to U.S. clinical research and evolving regulatory processes. UpDoc received FDA 510(k) clearance in December 2025 for patient-facing large language model software intended for insulin and medication management in adults with type 2 diabetes.

Europe followed North America in adoption, with Germany, the United Kingdom, and France serving as key national markets. Germany's DiGA pathway gave eligible digital health applications a route to reimbursement, supporting tailored product development. The European Union AI Act created planning requirements for companies selling in both European and U.S. settings, with high-risk obligations originally targeted for August 2026 and later proposed for December 2027. France and Spain advanced hospital digitization programs, while academic hospital pilots supported adoption in Italy. NHS England's April 2026 ambient scribing guidance offered a detailed operating framework for documentation products and helped health systems set practical expectations for governance and implementation.

Asia-Pacific is projected to register a 21.95% CAGR through 2031, making it the fastest-growing geography in the generative AI in SaMD market. China, India, Japan, and South Korea expanded digital health infrastructure and clinical AI programs. The supplied draft states that China's NMPA approved more than 120 AI medical device products in 2025. China's public hospital procurement system offered volume opportunities for domestic companies with local approvals, while international suppliers required locally validated datasets. Japan's PMDA revised its guidance for adaptive algorithms, and the Society 5.0 program treated AI-enabled healthcare software as a national priority.

1. Abbott Laboratories
2. Aidoc Medical Ltd.
3. AliveCor
4. Boston Scientific
5. Butterfly Network, Inc.
6. Butterfly Network, Inc.
7. Canon
8. Caption Health, Inc.
9. GE HealthCare Technologies Inc.
10. Intuitive Surgical, Inc.
11. iRhythm Technologies
12. Koninklijke Philips
13. Medtronic
14. Microsoft
15. NVIDIA
16. Paige.AI, Inc.
17. Siemens Healthineers
18. SOPHiA GENETICS SA
19. Tempus AI, Inc.
20. Viz.ai, Inc.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 Study Assumptions and Market Definition
• 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET LANDSCAPE

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Growth of AI-Assisted Clinical Documentation
  • 4.2.2 Expansion of Multimodal Clinical Data Workflows
  • 4.2.3 Rising Demand for Scalable Clinical Decision Support
  • 4.2.4 Regulatory Pathways for Managed Algorithm Changes
  • 4.2.5 Clinician Shortages and Diagnostic Workflow Pressure
  • 4.2.6 Foundation-Model Reuse Across Narrow Clinical Workflows
• 4.3 Market Restraints
  • 4.3.1 Hallucination and Non-Deterministic Clinical Outputs
  • 4.3.2 Limited Generative AI-Specific Clinical Evidence
  • 4.3.3 Patient-Level Data Governance and Provenance Constraints
  • 4.3.4 Liability Ambiguity for AI-Influenced Clinical Decisions
• 4.4 Value / Supply-Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
• 4.7 Porter's Five Forces Analysis
  • 4.7.1 Threat of New Entrants
  • 4.7.2 Bargaining Power of Suppliers
  • 4.7.3 Bargaining Power of Buyers
  • 4.7.4 Threat of Substitutes
  • 4.7.5 Competitive Rivalry

5 MARKET SIZE AND GROWTH FORECASTS (VALUE, USD)

• 5.1 By Software Function
  • 5.1.1 Clinical Documentation and Ambient Scribing
  • 5.1.2 Clinical Decision Support
  • 5.1.3 Diagnostic Interpretation and Reporting
  • 5.1.4 Patient Communication and Triage
  • 5.1.5 Therapeutic Planning and Personalization
  • 5.1.6 Remote Monitoring and Patient Management
  • 5.1.7 Medical Coding and Revenue-Cycle Support
  • 5.1.8 Clinical Trial and Evidence Generation Support
• 5.2 By Clinical Use Case
  • 5.2.1 Radiology and Imaging
  • 5.2.2 Pathology
  • 5.2.3 Oncology
  • 5.2.4 Cardiology
  • 5.2.5 Neurology
  • 5.2.6 Ophthalmology
  • 5.2.7 Gastroenterology
  • 5.2.8 Women's Health
  • 5.2.9 Others
• 5.3 By Deployment
  • 5.3.1 Cloud-Based
  • 5.3.2 On-Premises
  • 5.3.3 Hybrid
• 5.4 By End User
  • 5.4.1 Hospitals and Health Systems
  • 5.4.2 Ambulatory Care Centers
  • 5.4.3 Diagnostic Laboratories
  • 5.4.4 Specialty Clinics
  • 5.4.5 Academic Medical Centers
  • 5.4.6 Others
• 5.5 By Geography
  • 5.5.1 North America
    • 5.5.1.1 United States
    • 5.5.1.2 Canada
    • 5.5.1.3 Mexico
  • 5.5.2 Europe
    • 5.5.2.1 Germany
    • 5.5.2.2 United Kingdom
    • 5.5.2.3 France
    • 5.5.2.4 Italy
    • 5.5.2.5 Spain
    • 5.5.2.6 Rest of Europe
  • 5.5.3 Asia-Pacific
    • 5.5.3.1 China
    • 5.5.3.2 India
    • 5.5.3.3 Japan
    • 5.5.3.4 Australia
    • 5.5.3.5 South Korea
    • 5.5.3.6 Rest of Asia-Pacific
  • 5.5.4 Middle East and Africa
    • 5.5.4.1 GCC
    • 5.5.4.2 South Africa
    • 5.5.4.3 Rest of Middle East and Africa
  • 5.5.5 South America
    • 5.5.5.1 Brazil
    • 5.5.5.2 Argentina
    • 5.5.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global Level Overview, Market Level Overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share, Products and Services, Recent Developments)
  • 6.3.1 Abbott Laboratories
  • 6.3.2 Aidoc Medical Ltd.
  • 6.3.3 AliveCor, Inc.
  • 6.3.4 Boston Scientific Corporation
  • 6.3.5 Butterfly Network, Inc.
  • 6.3.6 Butterfly Network, Inc.
  • 6.3.7 Canon Medical Systems Corporation
  • 6.3.8 Caption Health, Inc.
  • 6.3.9 GE HealthCare Technologies Inc.
  • 6.3.10 Intuitive Surgical, Inc.
  • 6.3.11 iRhythm Technologies, Inc.
  • 6.3.12 Koninklijke Philips N.V.
  • 6.3.13 Medtronic plc
  • 6.3.14 Microsoft Corporation
  • 6.3.15 NVIDIA Corporation
  • 6.3.16 Paige.AI, Inc.
  • 6.3.17 Siemens Healthineers AG
  • 6.3.18 SOPHiA GENETICS SA
  • 6.3.19 Tempus AI, Inc.
  • 6.3.20 Viz.ai, Inc.

7 MARKET OPPORTUNITIES AND FUTURE OUTLOOK

• 7.1 White-Space and Unmet-Need Assessment